EMA on COVID-19: 'Fast-Tracking Does Not Mean Cutting Corners'

Agency Insists Safety And Efficacy Are Paramount

EMA advises caution on COVID-19 vaccine timelines, but says the outlook is more promising for new treatments.  

EU_Flag_Covid19
The EU's regulator explains its outlook on COVID-19 drug and vaccine development • Source: Shutterstock

The first treatments for COVID-19 could be granted a marketing authorization in the EU as soon as the summer if clinical trial results are positive, but a vaccine is unlikely to be available for another year, according to top executives at the European Medicines Agency.

Using fast-track mechanisms to speed up the development of coronavirus therapeutics and vaccines did not equate to “cutting corners” with...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography